Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PYGL | P06737 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KCNA6 | P17658 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1202583 | 0.91 | KDM4E (0.48) | KDM4EGAAALDH1A1MAPK1PYGL | |
| SCHEMBL13271499 | 0.85 | ALOX15 (0.56) | KDM4EALDH1A1PYGLKMT2ACHEK1 | |
| SCHEMBL2106985 | 0.83 | PYGL (0.52) | PYGLALOX15 | |
| SCHEMBL13271409 | 0.83 | CCNC (0.44) | PYGLKMT2AKCNA6KCNA3KCNA4 | |
| SCHEMBL4721594 | 0.82 | CHEK1 (0.44) | KDM4EALDH1A1PYGLKMT2ACHEK1 | |
| SCHEMBL3136945 | 0.82 | PYGL (0.44) | KDM4EGAAALDH1A1MAPK1PYGL | |
| SCHEMBL25758892 | 0.81 | ALOX15 (0.59) | KDM4EALDH1A1PYGLALOX15 | |
| Hydrochloric Acid SCHEMBL4400086 | 0.81 | CHEK1 (0.43) | KDM4EALDH1A1PYGLKMT2ACHEK1 | |
| SCHEMBL30189274 | 0.81 | F7 (0.56) | KDM4EALDH1A1MAPK1PYGLKMT2A | |
| SCHEMBL1203070 | 0.81 | F7 (0.56) | KDM4EALDH1A1MAPK1PYGLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884112-B2 | Glycogen phosphorylase inhibitor; antidiabetic agents; hypoglycemic agents; hypercholesterolemia; hypotensive agents; antilipemic agents; hypotensive agents; antiischemic agents | BRADLEY STUART EDWARD | 2011-02-08 | — | — | US | disclosed |
| US-7884112-B2 | Glycogen phosphorylase inhibitor; antidiabetic agents; hypoglycemic agents; hypercholesterolemia; hypotensive agents; antilipemic agents; hypotensive agents; antiischemic agents | BRADLEY STUART EDWARD | 2011-02-08 | — | — | US | disclosed |
| US-7884112-B2 | Glycogen phosphorylase inhibitor; antidiabetic agents; hypoglycemic agents; hypercholesterolemia; hypotensive agents; antilipemic agents; hypotensive agents; antiischemic agents | BRADLEY STUART EDWARD | 2011-02-08 | — | — | US | disclosed |
| EP-1725555-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PROSIDION LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| EP-1725555-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PROSIDION LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| US-20080269277-A1 | Pyrrolopyridine-2-Carboxylic Acid Hydrazides | BRADLEY STUART EDWARD | 2008-10-30 | — | — | US | disclosed |
| US-20080269277-A1 | Pyrrolopyridine-2-Carboxylic Acid Hydrazides | BRADLEY STUART EDWARD | 2008-10-30 | — | — | US | disclosed |
| US-20080269277-A1 | Pyrrolopyridine-2-Carboxylic Acid Hydrazides | BRADLEY STUART EDWARD | 2008-10-30 | — | — | US | disclosed |
| EP-1725555-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | Prosidion Ltd. (GB) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005089515-A9 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | BRIGHAM & WOMENS HOSPITAL (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005085245-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES | — | 2006-01-05 | — | — | WO | disclosed |
| WO-2005085245-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES | PROSIDION LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269277-A1 | Pyrrolopyridine-2-Carboxylic Acid Hydrazides | PYGL, PDK1, PYGM | KDM4E 2676/4885GAA 136/4885ALDH1A1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.